Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

NCT04479527 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Camrelizumab

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]